Loading...
Market
Story
FDA Releases Briefing Documents for Eli Lilly's Alzheimer's Drug Donanemab, Targeted Approval Considered
Jun 6, 2024, 02:43 PM
The FDA has released briefing documents for Eli Lilly's experimental Alzheimer's drug, donanemab. These documents include two voting questions with specific instructions from the agency. FDA staff are considering a more targeted approval for the treatment than Eli Lilly desires. A panel of outside experts will meet on Monday to vote on the safety and efficacy data for donanemab and make recommendations to the FDA. This drug is seen as a potential rival to Eisai and Biogen's Leqembi. FDA reviewers have raised questions about whether approval should be restricted to a smaller group of patients. Despite this, FDA staff have raised no major concerns about the drug. Eli Lilly shares were down 0.1% pre-market following the release of the documents.
View original story
Similar markets
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
United States • 25%
Europe • 25%
Asia • 25%
Other regions • 25%
Brain Bleeding • 33%
Brain Swelling • 33%
Other Side Effects • 34%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Exceed $500 million • 25%
Between $300 million and $500 million • 25%
Between $100 million and $300 million • 25%
Below $100 million • 25%
Achieve more than 15% market share • 25%
Achieve 10-15% market share • 25%
Achieve 5-10% market share • 25%
Achieve less than 5% market share • 25%
Above $5 billion • 25%
Between $3 billion and $5 billion • 25%
Between $1 billion and $3 billion • 25%
Below $1 billion • 25%
Less than $500 million • 33%
$500 million - $1 billion • 33%
More than $1 billion • 34%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%